JP2020523134A - 緑内障の治療のためのシステム、方法及び器具 - Google Patents
緑内障の治療のためのシステム、方法及び器具 Download PDFInfo
- Publication number
- JP2020523134A JP2020523134A JP2019568712A JP2019568712A JP2020523134A JP 2020523134 A JP2020523134 A JP 2020523134A JP 2019568712 A JP2019568712 A JP 2019568712A JP 2019568712 A JP2019568712 A JP 2019568712A JP 2020523134 A JP2020523134 A JP 2020523134A
- Authority
- JP
- Japan
- Prior art keywords
- drainage device
- glaucoma drainage
- eye
- rod
- inserter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims description 12
- 208000024304 Choroidal Effusions Diseases 0.000 claims abstract description 62
- 210000002159 anterior chamber Anatomy 0.000 claims abstract description 37
- 210000001742 aqueous humor Anatomy 0.000 claims abstract description 17
- 238000002513 implantation Methods 0.000 claims abstract description 9
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 16
- -1 styrene ethylene butylene styrene Chemical class 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 210000003161 choroid Anatomy 0.000 claims description 9
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 2
- 208000031872 Body Remains Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 10
- 210000001508 eye Anatomy 0.000 description 42
- 229920002988 biodegradable polymer Polymers 0.000 description 14
- 239000004621 biodegradable polymer Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 239000011159 matrix material Substances 0.000 description 12
- 210000003813 thumb Anatomy 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 239000007943 implant Substances 0.000 description 10
- 230000004410 intraocular pressure Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 5
- 210000003786 sclera Anatomy 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004240 ciliary body Anatomy 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001585 trabecular meshwork Anatomy 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 239000004642 Polyimide Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004323 axial length Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical class C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000023753 dehiscence Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- MBWFVZRQIIDYED-UHFFFAOYSA-N ethyl carbamate;2-methylprop-1-ene Chemical compound CC(C)=C.CCOC(N)=O MBWFVZRQIIDYED-UHFFFAOYSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 108010036236 extracellular matrix receptor Proteins 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001692 polycarbonate urethane Polymers 0.000 description 1
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920005591 polysilicon Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 210000001760 tenon capsule Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
- A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
Abstract
Description
本願は、2017年6月13日に出願された米国仮特許出願第62/518944の優先権を主張し、この全内容は参照によって本明細書に取り込まれる。
Claims (15)
- 遠位端部から近位端部まで軸線方向に延在する、管腔を有しない細長の本体であって、前記遠位端部が、先端の遠位縁を有する楔として形成され、該本体が、前記近位端部又は該近位端部の近傍から該本体の遠位端部に向かって延在する少なくとも一つの開放溝を画定する一つ以上の外面を有する、本体を備え、
前記細長の本体が、眼の前房からの房水が該眼の前房から該眼の脈絡膜上腔まで前記開放溝に沿って流れることを可能とすべく、該眼の脈絡膜上腔に留まり且つ該眼の前房内に延在するように構成される、緑内障排水装置。 - 前記本体が前記少なくとも一つの開放溝の遠位端部又は該遠位端部の近傍において当接部を画定し、又は該本体が、平面である上方外面及び下方外面を有する、請求項1に記載の装置。
- 前記本体が、ショア30A〜60Aの硬度を有する材料から形成される、請求項1に記載の装置。
- 前記本体が、ポリ(スチレンブロックイソブチレンブロックスチレン)(SIBS)、スチレンエチレンブチレンスチレン(SEBS)、ポリヘキセン、ポリプロピレン及びポリエチレンの少なくとも一つから形成される、請求項3に記載の装置。
- 遠位端部から近位端部まで軸線方向に延在する、管腔を有しない細長の本体を含む緑内障排水装置であって、前記遠位端部が、先端の遠位縁を有する楔として形成され、前記本体が、前記近位端部又は該近位端部の近傍から該本体の遠位端部に向かって延在する少なくとも一つの開放溝を画定する一つ以上の外面を有し、前記細長の本体が、眼の前房からの房水が該眼の前房から該眼の脈絡膜上腔まで前記開放溝に沿って流れることを可能とすべく、該眼の脈絡膜上腔に留まり且つ該眼の前房内に延在するように構成される、緑内障排水装置と、
前記緑内障排水装置に結合される挿入器であって、前記緑内障排水装置を前記脈絡膜上腔に送達して位置付け、且つ該緑内障排水装置から分離して該緑内障排水装置を該脈絡膜上腔において展開するように構成された挿入器と
を備える、緑内障装置キット。 - 前記挿入器が、ハンドルと、該ハンドルに対して長手方向に並進するように構成された少なくとも一つのロッドとを含み、該少なくとも一つのロッドが前記緑内障排水装置の本体の前記少なくとも一つの開放溝において長手方向に並進するように構成され、前記挿入器が前記緑内障排水装置に結合されると、前記ロッドが、該ロッドが前記緑内障排水装置の本体の前記開放溝の一部に少なくとも配置される伸長形態になる、請求項5に記載のキット。
- 前記挿入器が、前記伸長形態から、前記ロッドが前記緑内障排水装置の開放溝の一部に配置されない格納形態に前記少なくとも一つのロッドを再構成することによって前記緑内障排水装置から分離するように構成される、請求項6に記載のキット。
- 前記少なくとも一つのロッドが、ユーザの手によって作動されるように構成されたスライド部材に結合され、前記挿入器のハンドルが、該ハンドルの長さに沿って軸線方向に延在し且つ前記少なくとも一つのロッドと平行な長手方向のスロットを画定し、前記スライド部材が前記スロット内で摺動して前記伸長形態と前記格納形態との間で前記ロッドを移動させるように構成される、請求項7に記載のキット。
- 遠位端部から近位端部まで軸線方向に延在する、管腔を有しない細長の本体を含む緑内障排水装置を提供するステップであって、前記遠位端部が、先端の遠位縁を有する楔として形成され、前記本体が、前記近位端部又は該近位端部の近傍から該本体の遠位端部に向かって延在する少なくとも一つの開放溝を画定する一つ以上の外面を有し、前記細長の本体が、眼の前房からの房水が該眼の前房から該眼の脈絡膜上腔まで前記開放溝に沿って流れることを可能とすべく、該眼の脈絡膜上腔に留まり且つ該眼の前房内に延在するように構成される、ステップと、
前記緑内障排水装置に結合される挿入器を提供するステップであって、該挿入器が、ユーザによって把持されるように構成されたハンドルを有し、該挿入器が、前記緑内障排水装置を前記脈絡膜上腔に送達して位置付け、且つ該緑内障排水装置から分離して該緑内障排水装置を該脈絡膜上腔において展開するように構成される、ステップと、
前記眼の外側に前記ハンドルを維持しつつ、前記眼緑内障排水装置を前記眼内に導入するステップと、
前記緑内障排水装置を前記脈絡膜上腔の所望の埋込位置に位置決めするステップと、
前記緑内障排水装置が前記所望の埋込位置に位置決めされた状態で、前記挿入器を該緑内障排水装置から分離するステップと
を含む、緑内障排水装置を埋め込む方法。 - 前記緑内障排水装置を所望の埋込位置に位置決めするステップが、前記緑内障排水装置の遠位端部を前記脈絡膜上腔に位置決めし、前記緑内障排水装置の近位端部を前記前房に位置決めすることを含む、請求項9に記載の方法。
- 前記所望の位置において、前記緑内障排水装置が前記前房内に約0.5mm〜1mm延在する、請求項10に記載の方法。
- 前記本体が前記少なくとも一つの開放溝の遠位端部又は該遠位端部の近傍において当接部を画定する、請求項9に記載の方法。
- 前記挿入器が、前記ハンドルに対して長手方向に並進するように構成された少なくとも一つのロッドを含み、該少なくとも一つのロッドが前記緑内障排水装置の本体の前記少なくとも一つの開放溝において長手方向に並進するように構成され、前記挿入器が前記緑内障排水装置に結合されると、前記ロッドが、該ロッドが前記緑内障排水装置の本体の前記開放溝の一部に少なくとも配置される伸長形態になる、請求項9に記載の方法。
- 前記挿入器が、前記伸長形態から、前記ロッドが前記緑内障排水装置の本体の前記開放溝の一部に配置されない格納形態に前記少なくとも一つのロッドを再構成することによって前記緑内障排水装置から分離するように構成され、
前記挿入器を前記緑内障排水装置から分離するステップが、前記少なくとも一つのロッドを前記伸長形態から前記格納形態に再構成することを含む、請求項13に記載の方法。 - 前記少なくとも一つのロッドが、前記ユーザの手によって作動されるように構成されたスライド部材に結合され、前記挿入器のハンドルが、該ハンドルの長さに沿って軸線方向に延在し且つ前記前記少なくとも一つのロッドと平行な長手方向のスロットを画定し、前記スライド部材が前記スロット内で摺動して前記伸長形態と前記格納形態との間で前記ロッドを移動させるように構成される、請求項14に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023110024A JP7445809B2 (ja) | 2017-06-13 | 2023-07-04 | 緑内障の治療のためのシステム、方法及び器具 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762518944P | 2017-06-13 | 2017-06-13 | |
US62/518,944 | 2017-06-13 | ||
PCT/US2018/034301 WO2018231485A1 (en) | 2017-06-13 | 2018-05-24 | Systems, methods, and apparatus for treatment of glaucoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023110024A Division JP7445809B2 (ja) | 2017-06-13 | 2023-07-04 | 緑内障の治療のためのシステム、方法及び器具 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020523134A true JP2020523134A (ja) | 2020-08-06 |
JP7309624B2 JP7309624B2 (ja) | 2023-07-18 |
Family
ID=64660581
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019568712A Active JP7309624B2 (ja) | 2017-06-13 | 2018-05-24 | 緑内障の治療のためのシステム、方法及び器具 |
JP2023110024A Active JP7445809B2 (ja) | 2017-06-13 | 2023-07-04 | 緑内障の治療のためのシステム、方法及び器具 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023110024A Active JP7445809B2 (ja) | 2017-06-13 | 2023-07-04 | 緑内障の治療のためのシステム、方法及び器具 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11517476B2 (ja) |
EP (2) | EP4223263A1 (ja) |
JP (2) | JP7309624B2 (ja) |
CN (1) | CN110913809B (ja) |
CA (1) | CA3077101A1 (ja) |
ES (1) | ES2946142T3 (ja) |
TW (1) | TWI769264B (ja) |
WO (1) | WO2018231485A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI695716B (zh) * | 2019-03-26 | 2020-06-11 | 巨晰光纖股份有限公司 | 眼球排水之分流支架 |
CN111759582A (zh) * | 2019-04-02 | 2020-10-13 | 巨晰光纤股份有限公司 | 眼球排水的分流支架 |
CN114432034A (zh) * | 2021-12-22 | 2022-05-06 | 山东百多安医疗器械股份有限公司 | 一种可降解聚乳酸青光眼引流管 |
CN114939190B (zh) * | 2022-06-14 | 2024-01-12 | 健诺维(成都)生物科技有限公司 | 一种用于青光眼治疗的引流管材料及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
JP2012125606A (ja) * | 2006-01-17 | 2012-07-05 | Transcend Medical Inc | 緑内障処置装置 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
FR2721499B1 (fr) * | 1994-06-22 | 1997-01-03 | Opsia | Implant de trabéculectomie. |
US5601094A (en) * | 1994-11-22 | 1997-02-11 | Reiss; George R. | Ophthalmic shunt |
CN2287027Y (zh) | 1996-09-18 | 1998-08-05 | 张军锋 | 青光眼微型眼压调节器 |
US6004302A (en) | 1997-08-28 | 1999-12-21 | Brierley; Lawrence A. | Cannula |
US8313454B2 (en) * | 1997-11-20 | 2012-11-20 | Optonol Ltd. | Fluid drainage device, delivery device, and associated methods of use and manufacture |
US20050119601A9 (en) * | 1999-04-26 | 2005-06-02 | Lynch Mary G. | Shunt device and method for treating glaucoma |
US7708711B2 (en) * | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US7951155B2 (en) * | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
EP1689333B1 (en) | 2003-12-05 | 2014-02-12 | Innfocus, Inc. | Improved glaucoma implant device |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US7862531B2 (en) | 2004-06-25 | 2011-01-04 | Optonol Ltd. | Flow regulating implants |
US7594899B2 (en) * | 2004-12-03 | 2009-09-29 | Innfocus, Llc | Glaucoma implant device |
US7837644B2 (en) | 2004-12-03 | 2010-11-23 | Innfocus, Llc | Glaucoma implant device |
US7909789B2 (en) | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US8911496B2 (en) * | 2006-07-11 | 2014-12-16 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
WO2008061043A2 (en) * | 2006-11-10 | 2008-05-22 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
CN101199440B (zh) | 2006-12-12 | 2010-07-07 | 张传忠 | 泪道引流装置及放置该装置的泪道探条 |
JP5411140B2 (ja) * | 2007-09-07 | 2014-02-12 | キュー エル ティー インク. | 涙管インプラントの検出 |
US8409171B2 (en) * | 2008-02-28 | 2013-04-02 | Hollister Incorporated | Fluid drainage catheter having an external flow path |
CN201216683Y (zh) | 2008-06-23 | 2009-04-08 | 陈颖平 | 眼球角膜巩膜穿刺刀 |
CH700142A1 (de) | 2008-12-22 | 2010-06-30 | Grieshaber Ophthalmic Res Foun | Implantat zum einführen in den schlemmschen kanal eines auges. |
US8425473B2 (en) * | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
EP2548538B1 (en) * | 2009-01-28 | 2020-04-01 | Alcon Inc. | Implantation systems for ocular implants with stiffness qualities |
CA2762071A1 (en) * | 2009-05-15 | 2010-11-18 | Iscience Interventional Corporation | Methods and apparatus for sub-retinal catheterization |
US8764696B2 (en) * | 2009-06-16 | 2014-07-01 | Mobius Therapeutics, Inc. | Medical drainage devices with carbon-based structures for inhibiting growth of fibroblasts |
TW201127359A (en) * | 2009-09-21 | 2011-08-16 | Vidus Ocular Inc | Uveoscleral drainage device |
US20110098809A1 (en) * | 2009-10-23 | 2011-04-28 | John Wardle | Ocular Implant System and Method |
US8771216B2 (en) * | 2009-11-06 | 2014-07-08 | University Hospitals Of Cleveland | Fluid communication device and method of use thereof |
US8845572B2 (en) | 2009-11-13 | 2014-09-30 | Grieshaber Ophthalmic Research Foundation | Method and device for the treatment of glaucoma |
WO2011075481A1 (en) | 2009-12-16 | 2011-06-23 | Allergan, Inc. | Intracameral devices for sustained delivery |
US8663150B2 (en) * | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9101444B2 (en) | 2012-01-12 | 2015-08-11 | Innfocus, Inc. | Method, surgical kit and device for treating glaucoma |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
EP3228286A1 (en) * | 2012-09-17 | 2017-10-11 | Novartis AG | Expanding ocular impant devices |
US20160030242A1 (en) * | 2013-03-14 | 2016-02-04 | Hanita Lenses R.C.A. Ltd. | Miniature Glaucoma Shunt |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
CN103181842B (zh) | 2013-03-25 | 2014-12-10 | 中国人民解放军第三军医大学第一附属医院 | 眼科用板层巩膜刀 |
US9649223B2 (en) * | 2013-06-13 | 2017-05-16 | Innfocus, Inc. | Inserter for tubular medical implant devices |
KR101841545B1 (ko) * | 2013-11-14 | 2018-03-23 | 아큐시스, 인코포레이티드 | 안구내 션트 삽입기 |
US9044301B1 (en) | 2013-11-25 | 2015-06-02 | Innfocus, Inc. | Methods, systems and devices for treating glaucoma |
JP2017520327A (ja) * | 2014-07-01 | 2017-07-27 | インジェクトセンス, インコーポレイテッド | 眼内圧センサを移植するための方法およびデバイス |
CN104490515A (zh) | 2014-12-18 | 2015-04-08 | 肖真 | 青光眼阀和青光眼引流装置 |
CN104984420A (zh) | 2015-07-20 | 2015-10-21 | 王文 | 一种引流管 |
CN105434103B (zh) | 2015-12-29 | 2017-07-07 | 北京大学人民医院 | 一种微型青光眼引流植入装置及系统 |
-
2018
- 2018-05-24 US US16/621,079 patent/US11517476B2/en active Active
- 2018-05-24 EP EP23164959.1A patent/EP4223263A1/en active Pending
- 2018-05-24 WO PCT/US2018/034301 patent/WO2018231485A1/en unknown
- 2018-05-24 ES ES18818723T patent/ES2946142T3/es active Active
- 2018-05-24 EP EP18818723.1A patent/EP3638164B1/en active Active
- 2018-05-24 CA CA3077101A patent/CA3077101A1/en active Pending
- 2018-05-24 JP JP2019568712A patent/JP7309624B2/ja active Active
- 2018-05-24 CN CN201880039591.XA patent/CN110913809B/zh active Active
- 2018-06-07 TW TW107119574A patent/TWI769264B/zh active
-
2022
- 2022-10-31 US US17/977,830 patent/US20230051779A1/en active Pending
-
2023
- 2023-07-04 JP JP2023110024A patent/JP7445809B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
JP2012125606A (ja) * | 2006-01-17 | 2012-07-05 | Transcend Medical Inc | 緑内障処置装置 |
Also Published As
Publication number | Publication date |
---|---|
CN110913809A (zh) | 2020-03-24 |
CA3077101A1 (en) | 2018-12-20 |
US20200188172A1 (en) | 2020-06-18 |
US20230051779A1 (en) | 2023-02-16 |
TWI769264B (zh) | 2022-07-01 |
ES2946142T3 (es) | 2023-07-13 |
WO2018231485A1 (en) | 2018-12-20 |
EP3638164A4 (en) | 2021-03-10 |
EP3638164A1 (en) | 2020-04-22 |
CN110913809B (zh) | 2023-10-03 |
US11517476B2 (en) | 2022-12-06 |
TW201902435A (zh) | 2019-01-16 |
EP3638164B1 (en) | 2023-05-10 |
EP4223263A1 (en) | 2023-08-09 |
JP7445809B2 (ja) | 2024-03-07 |
JP2023118852A (ja) | 2023-08-25 |
JP7309624B2 (ja) | 2023-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6810090B2 (ja) | 緑内障を治療するための方法、外科キット及び器具 | |
JP7445809B2 (ja) | 緑内障の治療のためのシステム、方法及び器具 | |
US11839571B2 (en) | Ocular implant with stiffness qualities, methods of implantation and system | |
US7837644B2 (en) | Glaucoma implant device | |
US7594899B2 (en) | Glaucoma implant device | |
JP6043834B2 (ja) | 薬剤溶出眼内インプラント | |
JP5748407B2 (ja) | ブドウ膜強膜シャント | |
US20070118065A1 (en) | Glaucoma Implant Device | |
US20070141116A1 (en) | Glaucoma Implant Device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210519 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220523 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230419 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230705 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7309624 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |